JP2022505841A5 - - Google Patents
Info
- Publication number
- JP2022505841A5 JP2022505841A5 JP2021522518A JP2021522518A JP2022505841A5 JP 2022505841 A5 JP2022505841 A5 JP 2022505841A5 JP 2021522518 A JP2021522518 A JP 2021522518A JP 2021522518 A JP2021522518 A JP 2021522518A JP 2022505841 A5 JP2022505841 A5 JP 2022505841A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749818P | 2018-10-24 | 2018-10-24 | |
| US62/749,818 | 2018-10-24 | ||
| PCT/IB2019/059020 WO2020084492A1 (en) | 2018-10-24 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505841A JP2022505841A (ja) | 2022-01-14 |
| JP2022505841A5 true JP2022505841A5 (enExample) | 2022-10-07 |
| JP7398448B2 JP7398448B2 (ja) | 2023-12-14 |
Family
ID=68344933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522518A Active JP7398448B2 (ja) | 2018-10-24 | 2019-10-22 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11541055B2 (enExample) |
| EP (1) | EP3870577B1 (enExample) |
| JP (1) | JP7398448B2 (enExample) |
| KR (1) | KR20210084508A (enExample) |
| CN (1) | CN113195475A (enExample) |
| AR (1) | AR116798A1 (enExample) |
| AU (1) | AU2019364739B2 (enExample) |
| BR (1) | BR112021007362A2 (enExample) |
| CA (1) | CA3117289A1 (enExample) |
| CL (1) | CL2021001025A1 (enExample) |
| CO (1) | CO2021004679A2 (enExample) |
| CR (1) | CR20210207A (enExample) |
| DO (1) | DOP2021000062A (enExample) |
| EA (1) | EA202190854A1 (enExample) |
| ES (1) | ES3026145T3 (enExample) |
| IL (1) | IL282240B2 (enExample) |
| MA (1) | MA53973A (enExample) |
| MX (1) | MX2021004593A (enExample) |
| PE (1) | PE20211781A1 (enExample) |
| PH (1) | PH12021550813A1 (enExample) |
| PL (1) | PL3870577T3 (enExample) |
| PT (1) | PT3870577T (enExample) |
| SG (1) | SG11202103560YA (enExample) |
| TW (1) | TWI824041B (enExample) |
| WO (1) | WO2020084492A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| US11541055B2 (en) * | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112021025655A2 (pt) * | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| EP4066839A4 (en) | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| BR112022020933A2 (pt) * | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| MX2024004551A (es) * | 2021-10-13 | 2024-06-26 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana. |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| AU2024353051A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical compositions |
| AU2023466962A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004023100D1 (de) | 2003-10-08 | 2009-10-22 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidemie |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| JP2012201642A (ja) * | 2011-03-25 | 2012-10-22 | Tsutomu Takeuchi | １−フェニルピロリジン−２，５−ジオン誘導体を有効成分とするｂａｆｆの結合阻害剤 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| US10065953B2 (en) * | 2014-08-27 | 2018-09-04 | VIIV Healthcare UK (No.5) Limited | Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| EP3186239B1 (en) * | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| EP3833436A1 (en) | 2018-08-09 | 2021-06-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3849982A1 (en) | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| FR3086760A1 (fr) | 2018-10-02 | 2020-04-03 | Institut Mines Telecom | Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique |
| US11541055B2 (en) * | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2971987T3 (es) | 2018-10-24 | 2024-06-10 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| JP7500555B2 (ja) | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| EP3873607B1 (en) | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US11429555B2 (en) | 2019-02-26 | 2022-08-30 | Apple Inc. | Coprocessors with bypass optimization, variable grid architecture, and fused vector operations |
| CA3078001A1 (en) | 2019-04-11 | 2020-10-15 | Goli Nutrition Inc. | Apple cider vinegar nutritional supplement |
| US20220211704A1 (en) | 2019-04-30 | 2022-07-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112021025655A2 (pt) | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| EP4038068A1 (en) | 2019-10-01 | 2022-08-10 | VIIV Healthcare UK (No.5) Limited | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| EP4038064B1 (en) | 2019-10-01 | 2024-02-21 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4114527A1 (en) | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-10-22 US US16/762,209 patent/US11541055B2/en active Active
- 2019-10-22 CR CR20210207A patent/CR20210207A/es unknown
- 2019-10-22 EP EP19794683.3A patent/EP3870577B1/en active Active
- 2019-10-22 PT PT197946833T patent/PT3870577T/pt unknown
- 2019-10-22 CN CN201980085915.8A patent/CN113195475A/zh active Pending
- 2019-10-22 JP JP2021522518A patent/JP7398448B2/ja active Active
- 2019-10-22 MA MA053973A patent/MA53973A/fr unknown
- 2019-10-22 EA EA202190854A patent/EA202190854A1/ru unknown
- 2019-10-22 BR BR112021007362-0A patent/BR112021007362A2/pt unknown
- 2019-10-22 PL PL19794683.3T patent/PL3870577T3/pl unknown
- 2019-10-22 AU AU2019364739A patent/AU2019364739B2/en active Active
- 2019-10-22 TW TW108138086A patent/TWI824041B/zh active
- 2019-10-22 CA CA3117289A patent/CA3117289A1/en active Pending
- 2019-10-22 AR ARP190103016A patent/AR116798A1/es not_active Application Discontinuation
- 2019-10-22 IL IL282240A patent/IL282240B2/en unknown
- 2019-10-22 WO PCT/IB2019/059020 patent/WO2020084492A1/en not_active Ceased
- 2019-10-22 ES ES19794683T patent/ES3026145T3/es active Active
- 2019-10-22 PE PE2021000571A patent/PE20211781A1/es unknown
- 2019-10-22 KR KR1020217015003A patent/KR20210084508A/ko not_active Ceased
- 2019-10-22 MX MX2021004593A patent/MX2021004593A/es unknown
- 2019-10-22 SG SG11202103560YA patent/SG11202103560YA/en unknown
-
2021
- 2021-04-08 PH PH12021550813A patent/PH12021550813A1/en unknown
- 2021-04-09 DO DO2021000062A patent/DOP2021000062A/es unknown
- 2021-04-14 CO CONC2021/0004679A patent/CO2021004679A2/es unknown
- 2021-04-22 CL CL2021001025A patent/CL2021001025A1/es unknown
-
2022
- 2022-09-30 US US17/957,569 patent/US20230109662A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505841A5 (enExample) | ||
| JP2022505597A5 (enExample) | ||
| JP2022501370A5 (enExample) | ||
| JP2022505637A5 (enExample) | ||
| JP2022500425A5 (enExample) | ||
| JP2022505989A5 (enExample) | ||
| JP2024543983A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2022141835A5 (enExample) | ||
| JP2025071130A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2022547558A5 (enExample) | ||
| JP2024173998A5 (enExample) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| JP2016527217A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| RU2003137561A (ru) | 4-замещенные нуклеозиды | |
| JP2013209405A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2017519025A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2023544716A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication |